Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q4 FY2023 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, May 2023
Slide 1: IOL Chemicals and Pharmaceuticals Limited Q4 & FY23 Investor Presentation
IOL Chemicals and Pharmaceuticals Limited Q4 & FY23 Investor Presentation May 2023
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 3: Table of Contents
Table of Contents 02 Financial Highlights Quarterly Income Statement 01 IOLCP at a glance Half yearly Income statement 03 Company Overview Growing top-line The Journey About IOL Chemicals and Pharmaceuticals Ltd. Building Assets Core management team Q4 & FY23 Performance Cash Flow Statement Board of
Slide 4: IOL Chemicals & Pharma - Overview
IOL Chemicals & Pharma - Overview Incorporated in 1986, IOLCP is one of the leading API Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2300+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited) Debt free
Slide 5: Q4 & FY23 Performance
Q4 & FY23 Performance Q4FY23 Financial Performance Operational Highlights 587.2 104.5 17.5% Revenues (Rs. cr) EBITDA (Rs. cr) EBITDA Margin • The company received patent for “an improved safe process for the preparation of Sartan drugs of Formula I” by Indian Patent 65.3 11.0% Profit After Tax PAT M
Slide 6: Geographical and Segmental highlights
Geographical and Segmental highlights Chemical Segment (Rs. crore) Pharma Segment (Rs. crore) 300 13 15 400 368 90 11 350 80 80 10 297 303 303 300 285 250 70 5 250 60 200 -1 0 50 -3 150 40 200 -6 33 35 40 100 -5 50 24 30 276 279 238 218 219 150 -10 0 20 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q4FY22 Q1FY
Slide 7: Financial Highlights
FINANCIAL HIGHLIGHTS
Slide 8: Quarterly Income Statement
Quarterly Income Statement Particulars (Rs. Cr) Q4 FY23 Q4 FY22 YoY Q3 FY23 QoQ Revenues 587.2 572.5 523.5 Other Income 8.7 6.9 6.6 Total Income 595.9 579.4 2.8% 530.1 12.4% Total Expenses 491.4 529.4 480.4 EBITDA 104.5 50.0 108.8% 49.7 110.3% EBITDA Margin (%) 17.5% 8.6% 890 bps 9.4% 810 bps Deprec
Slide 9: Yearly Income Statement
Yearly Income Statement Particulars (Rs. Cr) FY23 FY22 YoY Revenues 2,217.1 2,184.0 Other Income 25.6 32.0 Total Income 2,242.7 2,216.0 1.2% Total Expenses 1,990.6 1,927.6 EBITDA 252.1 288.4 -12.6% EBITDA Margin (%) 11.2% 13.0% -180 bps Depreciation 46.1 43.3 Finance Cost 16.5 8.3 Profit Before Exce
Slide 10: Growing top-line
Growing top-line Particulars (Rs. Cr) FY18 FY19 FY20 FY21 FY22 FY23 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 2,217.1 Other Income 6.3 10.4 16.0 24.3 32.0 25.6 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 2,242.7 Total Expenses 863.7 1,275.7 1,320.6 1,375.2 1,927.6 1,990.6 EBITDA 125.9 42
Slide 11: Building assets
Building assets Balance Sheet (Rs. Cr) FY18 FY19 FY20 FY21 FY22 FY23 Shareholders' Funds 215.7 474.3 813.5 1260.4 1390.3 1506.6 Debt 421.9 284.0 56.0 0.0 0.0 0.0 Total Non-current Liabilities 33.6 20.8 79.7 59.1 56.6 58.1 Total Current Liabilities 180.9 162.8 220.6 290.6 513.4 455.9 Equity & Liabili
Slide 12: Cash Flow Statement
Cash Flow Statement Particulars (Rs. Cr) FY19 FY20 FY21 FY22 FY23 Profit before tax 336.15 533.24 571.39 222.84 189.49 Adjustments for: Non Cash Items / Other Investment or 82.35 51.93 27.15 33.12 44.42 Financial Items Operating profit before working capital changes 418.50 585.17 598.54 255.96 233.9
Slide 13: 5-years Performance
5-years Performance Operational Revenue (Rs Cr) EBITDA (Rs Cr) and EBITDA Margin (%) PAT (Rs Cr) and PAT Margin (%) 2,216 2,243 30.9% 30.9% 22.3% 1,911 1,991 18.9% 1,696 24.8% 13.0% 14.0% 990 12.7% 11.2% 7.5% 6.2% 2.8% 126 420 590 616 288 252 28 237 361 445 166 140 FY18 FY19 FY20 FY21 FY22 FY23 FY18
Slide 14: Diversified revenue base
Diversified revenue base FY22 FY23 FY18 362, 37% 1181, 54% 955, 43% 35, 3% 476, 22% 351, 16% 586, 60% 652, 30% 786, 35% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's • Contribution of non-Ibuprofen drugs has increased from Rs.35 crore in 2018 to Rs.4
Slide 15: Company Overview
COMPANY OVERVIEW
Slide 16: The Journey
The Journey 2009 - Commencement of 2015 - USFDA, EIR for 2019 - Unit-06 for 1996 - Commencement of IBB, MCA and Acetyl Commenced Ibuprofen Pantoprazole (Dedicated) Ethyl Acetate Plant Chloride Plants commercial production 2016 - Unit-03 for new 2020 - Unit-07 Metformin 1999 - Commenc
Slide 17: Core management team
Core management team Varinder Gupta (Managing Director) Wide and rich experience of more than 35 years in the chemical & fertilizer industry and along Vikas Gupta with a comprehensive approach and strong (Joint Managing Director) Pharma API industry oversight has paved a way Academically equippe
Slide 18: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 19: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 20: Business Overview
BUSINESS OVERVIEW
Slide 21: Pharmaceuticals – Building API portfolio
Pharmaceuticals – Building API portfolio IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen having a capacity of 12000+ MT • Among the largest producer of Metformin in
Slide 22: Specialty chemicals – capitalizing on global demand
Specialty chemicals – capitalizing on global demand IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 TPA Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 TPA • India’s se
Slide 23: Manufacturing facilities
Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated and multiproduct blocks system, PSA Nitrogen & Purified water continuous product delivery manner involved in manufacturing of APIs along with
Slide 24: Core sustainability pillars
Core sustainability pillars Environment Social Governance Strive to minimize the adverse impact Construction and renovation of schools Implemented a sound and well- on environment, health and Safety by and provided technical equipment for structured corporate governance that upgrading technolo
Slide 25: Industry Overview
INDUSTRY OVERVIEW
Slide 26: Pharmaceuticals – Emerging strongly out of pandemic
Pharmaceuticals – Emerging strongly out of pandemic Indian API Market World Pharmaceutical Industry • Pharmaceutical exports have registered a 3.25 per cent growth in FY23 at $25.3 billion. In 2021-22, the exports growth was almost flat at 0.71 per cent at $24.62 billion $1.5 3-6% $2.4 Trillion (202
Slide 27: Specialty Chemicals - an era of sustained robust growth
Specialty Chemicals - an era of sustained robust growth • India is expected to become a $850-1000 Bn chemicals market by 2040, taking 10-12% share of the global Indian Specialty Chemical Industry chemicals market • The sector is projected to grow at 11-12% during 2021- Specialty 27 and 7-10% during
Slide 28: Way Forward
WAY FORWARD
Slide 29: Way forward
Way forward Four pronged strategy for growth Focus on Capacity Improved Expanding Regulated expansion in asset Non-Ibuprofen Markets Pharma & utilization Business Chemicals Focus on efficiently utilizing Plan to enhance our product Target non- Ibuprofen business Capacity expansion for existing asset
Slide 30: Summary
Summary Pharmaceutical Segment • Most reliable partner for reputed pharmaceutical players globally, by providing them with high-quality input products, which are key ingredients used for making essential and advanced medicines. • Moving towards a well diversified product portfolio, that is a shift t
Slide 31: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals & Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Snighter Albuquerque CFO snighter.a@adfactorspr.com pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q4 FY2023 Earnings Presentation on 6ix